The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.
This paper describes a small retrospective observational study of Israeli travellers presenting to a tropical medicine clinic with a history of prolonged (4 weeks), non-traumatic arthralgia or arthritis over a 5 year period.
In the context of an active nationwide surveillance network, this study describes pneumoccocal meningitis in children aged from 1 day to 15 years during a 8 year study period (2001-2008) in France. 951 pneumoccocal meningitis cases were reported among 3312 children with bacterial meningitis. T
This descriptive study, based on national surveillance data of reported malaria cases, travelers’ statistics and data on malaria chemoprophylaxis prescriptions, estimates the incidence and trends of imported malaria in the Netherlands.
This paper describes the results of an open-label randomized trial, comparing the use of artesunate and quinine for the treatment of severe Plasmodium falciparum malaria in children in 11 African countries.
The appearance of West Nile virus in New York in 1999 and the unprecedented panzootic that followed, have stimulated a major research effort in the western hemisphere and a new interest in the presence of this virus in the Old World. This review considers current understanding of the natural history of this pathogen, with particular regard to transmission in Europe.
Following an outbreak of chikungunya in the area of Ravenna, Italy in Summer 2007 and the increasing presence of Aedes albopictus mosquitoes in Europe, ECDC has prepared a Chikungunya Communications Toolkit. It provides template materials containing background information and practical advice on chikungunya prevention and control and is targeting the general public, travellers and health practitioners.